Hyphen Pharma’s profit sinks 66.3% in H1

This was amidst a decrease in revenue.

Hyphens Pharma International Limited’s net profit after tax declined by 66.3% year on year to $2m during the first half of the year, amidst a decrease in revenue.

The 18.9% YoY decline in revenue in the Pharmaceutical and Medical Aesthetics segment was mainly due to lower sales in Vietnam.

Moreover, the Digital Platform and E-Pharmacy segment saw a YoY decrease of 5.9% to $20.4m.

However, the Proprietary Brands segment grew by 22.5% YoY to $17.4m, with the expansion of its portfolio, and higher demand for Ceradan® dermatological products and Ocean Health® health supplements.

Basic earnings per share stood at $0.54.

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.

The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.

So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia